Skip to main content

Table 4 Adverse events

From: Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)

 

Total

Grade

 

N(%)

1

2

3 – 4

Sirolimus (n = 23)

    

   At least 1 toxicity reported

14 (60)

   

   Intestinal toxicity

8 (34)

7

1

 

   Skin toxicity, infections

1 (4)

1

1

 

   Hematologic toxicity

6 (26)

1

1

4

   Urinary toxicity

1 (4)

  

1

   Neurological toxicity

3 (13)

2

1

 

   Other (fatigue, pain)

6 (26)

4

2

 

   Dose modification

2 (9)

   

   Discontinuation for toxicity

1 (4)

   

Sunitinib (n = 5)

    

   At least 1 toxicity reported

4 (80)

   

   Hematologic toxicity

2 (40)

 

2

 

   Pulmonary toxicity

1 (20)

  

1

   Other (fatigue)

2 (40)

2

 

1

   Dose modification

1 (20)

   

Sorafenib (n = 4)

    

   At least 1 toxicity reported

3 (75)

   

   Skin toxicity, infections

2 (50)

 

1

1

   other (fatigue, psychological)

4 (100)

 

1

2

   Dose modification

2 (50)

   

Pazopanib (n = 1)

    

   At least 1 toxicity reported

1

   

   Intestinal toxicity

1

 

1

 

   Other (fatigue)

1

  

1

   Dose modification

0

   

Total

≥1 AE: 22

17

11

11